Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00042410.xml
Download PDF
CC BY-NC-ND 4.0 · Rev Bras Ortop (Sao Paulo) 2021; 56(05): 550-557
DOI: 10.1055/s-0040-1714219
DOI: 10.1055/s-0040-1714219
Artigo de Atualização
Osteometabólicas
Atualização do Tratamento Medicamentoso da Osteoporose
Article in several languages: português | English
Resumo
A população brasileira está envelhecendo, e com isso aumenta a prevalência de doenças crônico-degenerativas, dentre elas a osteoporose. O diagnóstico e tratamento da osteoporose teve avanços significativos na última década. O ortopedista e traumatologista não pode mais se deter apenas no tratamento cirúrgico da fratura osteoporótica. É extremamente importante que saibamos: 1) quais fatores de risco avaliar, podendo ser utilizada a ferramenta Fracture Risk Assesment Tool (FRAX, na sigla em inglês); 2) quais exames complementares solicitar, como densitometria, radiografia da coluna e bacia, exames de sangue e urina, e até mesmo biópsia óssea; 3) quais suplementos utilizar, como cálcio e magnésio, vitaminas D e K; 4) quais medicamentos prescrever, antirreabsortivos ou formadores, janelas terapêuticas e eventos adversos.
Publication History
Received: 03 February 2020
Accepted: 15 April 2020
Article published online:
28 October 2021
© 2021. Sociedade Brasileira de Ortopedia e Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
Referências
- 1 Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med 2016; 374 (03) 254-262
- 2 de Souza MP. Osteoporosis Diagnosis and Treatment. Rev Bras Ortop 2010; 45 (03) 220-229
- 3 Stolnick B, Oliveira LG. Para que a primeira fratura seja a última. Rev Bras Ortop 2016; 51 (02) 121-126
- 4 Freedman BA, Potter BK, Nesti LJ, Cho T, Kuklo TR. Missed opportunities in patients with osteoporosis and distal radius fractures. Clin Orthop Relat Res 2007; 454 (454) 202-206
- 5 Souza BGSE, Carvalho LGVA, Oliveira LFMM, Ferreira AG, Amaral RCSD, Oliveira VM. Primary and secondary osteoporotic fractures prophylaxis: evaluation of a prospective cohort. Rev Bras Ortop 2017; 52 (05) 538-543
- 6 Radominski SC, Bernardo W, Paula AP, Albergaria BH, Moreira C, Fernandes CE. Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós-menopausa. Rev Bras Reumatol 2017; 57 (Suppl. 02) s452-s466
- 7 Oliveira LG, Guimarães ML. Male osteoporosis. Rev Bras Ortop 2015; 45 (05) 392-396
- 8 Banefelt J, Åkesson KE, Spångéus A. et al. Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos Int 2019; 30 (03) 601-609
- 9 Sousa CJ, Oliveira ML. Ferramenta FRAX no Brasil: revisão integrativa da literatura após sua Validação. Rev Bras Geriatr Gerontol 2018; 21 (01) 111-118
- 10 Bauer DC. Clinical practice. Calcium supplements and fracture prevention. N Engl J Med 2013; 369 (16) 1537-1543
- 11 Peters BS, Martini LA. Nutritional aspects of the prevention and treatment of osteoporosis. Arq Bras Endocrinol Metabol 2010; 54 (02) 179-185
- 12 Chen LR, Wen YT, Kuo CL, Chen KH. Calcium and Vitamin D Supplementation on Bone Health: Current Evidence and Recommendations. Int J Gerontol 2014; 8: 183-188
- 13 Kanis JA, Cooper C, Rizzoli R, Reginster JY. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2019; 30 (01) 3-44
- 14 Maeda SS, Borba VZ, Camargo MB. et al. Brazilian Society of Endocrinology and Metabology (SBEM). Recommendations of the Brazilian Society of Endocrinology and Metabology (SBEM) for the diagnosis and treatment of hypovitaminosis D. Arq Bras Endocrinol Metabol 2014; 58 (05) 411-433
- 15 Qaseem A, Forciea MA, McLean RM, Denberg TD. Clinical Guidelines Committee of the American College of Physicians. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med 2017; 166 (11) 818-839
- 16 Matzkin EG, DeMaio M, Charles JF, Franklin CC. Diagnosis and Treatment of Osteoporosis: What Orthopaedic Surgeons Need to Know. J Am Acad Orthop Surg 2019; 27 (20) e902-e912
- 17 Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010; 95 (04) 1555-1565
- 18 Maeda SS, Lazaretti-Castro M. An overview on the treatment of postmenopausal osteoporosis. Arq Bras Endocrinol Metabol 2014; 58 (02) 162-171
- 19 Khan AA, Morrison A, Hanley DA. et al. International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30 (01) 3-23
- 20 Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?. N Engl J Med 2012; 366 (22) 2051-2053
- 21 Zanatta LB, Marcattoa C, Ramosa CS, Manasa N, Moreira C, Borba V. Uso de pamidronato para tratamento da osteoporose no sistema público de saúde no Brasil. Rev Bras Reumatol 2017; 57 (06) 514-520
- 22 Kates SL, Ackert-Bicknell CL. How do bisphosphonates affect fracture healing?. Injury 2016; 47 (01 Suppl 1): S65-S68
- 23 Oliveira LG, Eis SR, Neto HM, de Moraes FB, Pires LA, Vasconcelos JW. Use of risedronate for consolidation and callus formation in Colles fractures in postmenopausal women: SOLID study. Rev Bras Ortop 2015; 50 (03) 274-282
- 24 Cummings SR, Ferrari S, Eastell R. et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res 2018; 33 (02) 190-198
- 25 Protocolos clínicos e diretrizes terapêuticas: volume 3 / Ministério da Saúde, Secretaria de Atenção à Saúde. Brasília: Ministério da Saúde; 2014. Disponível em: http://portalsaude.saude.gov.br/index.php/o-ministerio/principal/leia-mais-oministerio/840-sctie-raiz/daf-raiz/cgceaf-raiz/cgceaf/l3-cgceaf/11646-pcdt
- 26 Chesnut III CH, Silverman S, Andriano K. et al. PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109 (04) 267-276
- 27 Haas AV, LeBoff MS. Osteoanabolic Agents for Osteoporosis. J Endocr Soc 2018; 2 (08) 922-932
- 28 Neer RM, Arnaud CD, Zanchetta JR. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344 (19) 1434-1441
- 29 Pereira RM, Carvalho JF, Paula AP. et al. Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide. Rev Bras Reumatol 2012; 52 (04) 569-593
- 30 Iwata A, Kanayama M, Oha F, Hashimoto T, Iwasaki N. Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study. BMC Musculoskelet Disord 2017; 18 (01) 148
- 31 Gonnelli S, Caffarelli C. Abaloparatide. Clin Cases Miner Bone Metab 2016; 13 (02) 106-109
- 32 Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM. Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors. J Bone Miner Res 2017; 32 (01) 17-23
- 33 McClung MR, Grauer A, Boonen S. et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370 (05) 412-420